Ruben Aleman, MD
Family Medicine · McAllen, TXNPI 1447227608
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,959 of the $4,047 with a category attached, or 73.1%. 23 manufacturers reported payments, led by Pfizer at 46.3% of the total. Reporting peaked in 2019 at $2,000 and has fallen 89.8% since, to $205 in 2025.
Across 149 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Novo Nordisk$295
- Lilly USA, LLC$291
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$271
- Boehringer Ingelheim$245
- Organon$119
- plus $953 from 17 others
Across 116 payments — averaging $4407.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$504K
- Sanofi Pasteur Inc.$7K
What the payments were for
- Travel & lodging$1,07427%
- Food & beverage$2,95973%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $1,874 |
| Novo Nordisk | 19 | $295 |
| Lilly USA, LLC | 18 | $291 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $271 |
| Boehringer Ingelheim | 10 | $245 |
| Organon | 9 | $119 |
| Abbott | 6 | $114 |
| GSK | 7 | $113 |
| AstraZeneca | 7 | $112 |
| AbbVie(2 entities) | 6 | $101 |
| Exact Sciences | 4 | $89 |
| Amgen(2 entities) | 5 | $73 |
| Cumberland Pharmaceuticals, Inc. | 5 | $66 |
| Genentech USA, Inc. | 3 | $51 |
| Seqirus USA Inc | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Evofem Biosciences, Inc. | 1 | $24 |
| Mannkind Corporation | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
How this compares
$4,047 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $114,803 |
| JardianceEmpagliflozin | 87 | $95,575 |
| JanuviaSitagliptin Phosphate | 93 | $59,404 |
| MounjaroTirzepatide | 25 | $38,377 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $37,469 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $33,701 |
| LinzessLinaclotide | 26 | $28,341 |
| RybelsusSemaglutide | 16 | $27,994 |
| EliquisApixaban | 24 | $24,776 |
| MyrbetriqMirabegron | 25 | $22,023 |
| FarxigaDapagliflozin Propanediol | 19 | $21,303 |
| TradjentaLinagliptin | 27 | $19,367 |
| ProliaDenosumab | 11 | $19,246 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $14,635 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $295 | $142,798115 claims |
| Boehringer IngelheimJardiance, Tradjenta | $245 | $114,941114 claims |
| Lilly USA, LLCMounjaro | $291 | $38,37725 claims |
| GSKTrelegy Ellipta | $113 | $33,70129 claims |
| PfizerEliquis, Paxlovid | $1,874 | $28,85445 claims |
| AbbVieLinzess | $101 | $28,34126 claims |
| AstraZenecaFarxiga | $112 | $21,30319 claims |
| AmgenProlia | $73 | $19,24611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in McAllen
- Joel SolisMcAllen$324K
- Enrique GriegoMcAllen$179K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.